CliffBio
small molecule

CAMZYOS

MAVACAMTEN

Loss of exclusivityApril 2036latest FDA-listed patent expiry
CompanyBRISTOL MYERS SQUIBB CO

Drug detail

Brand nameCAMZYOS
Active ingredientMAVACAMTEN
Strength5MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2022
Marketing statusRX

Listed patents

PatentExpiresType
RE50050April 2036substance, product
9585883June 2034use U-3373

Regulatory exclusivity

CodeExpires
ODE-398April 2029
NCEApril 2027
M-297June 2026

More from BRISTOL MYERS SQUIBB CO

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CAMZYOS patent cliff — loss of exclusivity April 2036 | CliffBio